# Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects

> **NCT07588646** · PHASE1 · COMPLETED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** HEC585
- **DRUG:** Nintedanib
- **DRUG:** Pirfenidone

## Key facts

- **NCT ID:** NCT07588646
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-29
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-11-30
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07588646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07588646, "Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07588646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*